MX393754B - Metodos y composiciones para inhibir cnksr1 - Google Patents

Metodos y composiciones para inhibir cnksr1

Info

Publication number
MX393754B
MX393754B MX2019015648A MX2019015648A MX393754B MX 393754 B MX393754 B MX 393754B MX 2019015648 A MX2019015648 A MX 2019015648A MX 2019015648 A MX2019015648 A MX 2019015648A MX 393754 B MX393754 B MX 393754B
Authority
MX
Mexico
Prior art keywords
methods
compositions
cnksr1
inhibiting
inhibiting cnksr1
Prior art date
Application number
MX2019015648A
Other languages
English (en)
Inventor
D Lynn Kirkpatrick
Martin Indarte
Nathan T Ihle
Original Assignee
Phusis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phusis Therapeutics Inc filed Critical Phusis Therapeutics Inc
Publication of MX393754B publication Critical patent/MX393754B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Las modalidades incluyen composiciones y métodos para inhibir CNKSR1 y métodos para identificar los inhibidores de CNKSR1.
MX2019015648A 2012-12-14 2013-12-16 Metodos y composiciones para inhibir cnksr1 MX393754B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261737658P 2012-12-14 2012-12-14
PCT/US2013/075505 WO2014093988A2 (en) 2012-12-14 2013-12-16 Methods and compositions for inhibiting cnksr1

Publications (1)

Publication Number Publication Date
MX393754B true MX393754B (es) 2025-03-24

Family

ID=50935099

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015007608A MX372739B (es) 2012-12-14 2013-12-16 Metodos y composiciones para inhibir cnksr1.
MX2019015648A MX393754B (es) 2012-12-14 2013-12-16 Metodos y composiciones para inhibir cnksr1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015007608A MX372739B (es) 2012-12-14 2013-12-16 Metodos y composiciones para inhibir cnksr1.

Country Status (7)

Country Link
US (1) US9340532B2 (es)
EP (1) EP2931280B1 (es)
JP (1) JP6357292B2 (es)
AU (1) AU2013358876B2 (es)
CA (1) CA2895162C (es)
MX (2) MX372739B (es)
WO (1) WO2014093988A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014093988A2 (en) 2012-12-14 2014-06-19 Phusis Therapeutics, Inc. Methods and compositions for inhibiting cnksr1
US10227356B2 (en) * 2015-04-20 2019-03-12 Phusis Therapeutics, Inc. Compounds, compositions and methods for inhibiting CNKSR1
WO2018125983A1 (en) 2016-12-30 2018-07-05 Mitobridge, Inc. Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors
CN110698411B (zh) * 2018-07-09 2023-05-09 四川大学 一类4-(胺烷基)酞嗪-1-酮类化合物、其制备方法和用途
WO2022026465A1 (en) * 2020-07-28 2022-02-03 Mirati Therapeutics, Inc. Sos1 inhibitors
WO2022187804A1 (en) * 2021-03-02 2022-09-09 Icahn School Of Medicine At Mount Sinai Benzoxazolone inhibitors of inflammasomes
WO2024192873A1 (zh) * 2023-03-20 2024-09-26 杭州天玑济世生物科技有限公司 一类具有萘胺结构的小分子化合物的用途
CN116444477A (zh) * 2023-04-04 2023-07-18 宁波九胜创新医药科技有限公司 一种溴代胡椒环羧酸的制备方法及其用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA775563A (en) 1968-01-09 Frank W. Horner Limited Hypoglycemic thiadiazoles
GB828963A (en) 1956-08-03 1960-02-24 Rhone Poulenc Sa Pharmaceutical compositions containing 2-p-aminobenzenesulphonamido-5-t-butyl-1, 3, 4-thiadiazole
US3821222A (en) 1971-11-22 1974-06-28 Chevron Res Hydrocarbyl sulfenylmercapto pyrimidines
US4017489A (en) 1975-07-10 1977-04-12 The Goodyear Tire & Rubber Company Process of preparing unsymmetrical disulfides
DE2556011A1 (de) 1975-12-12 1977-06-23 Merck Patent Gmbh Disulfide
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
GB2152497B (en) 1983-11-28 1987-08-05 Otsuka Kagaku Kk Process for the preparation of azetidinone derivatives
FR2573077B1 (fr) 1984-11-13 1987-02-13 Sanofi Sa Nouveaux derives thiosulfonates, leur procede de preparation ainsi que les compositions pharmaceutiques les contenant
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4990523A (en) 1989-06-19 1991-02-05 A. H. Robins Company, Incorporated Treatment of chronic inflammatory joint disease with arylsulfonamides
GB9507415D0 (en) * 1994-06-08 1995-05-31 Zylepsis Ltd Production and uses of caffeic acid and derivatives thereof
US6139875A (en) 1998-09-29 2000-10-31 Eastman Chemical Company Aqueous enteric coating composition and low gastric permeability enteric coating
FR2815032B1 (fr) 2000-10-10 2003-08-08 Pf Medicament Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations
CA2442264A1 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. A method of treating cancer
EP1423120A4 (en) * 2001-08-15 2005-12-28 Icos Corp 2H-PHTALAZINE-1-ONES AND METHODS OF USE THEREOF
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
WO2003084473A2 (en) 2002-04-08 2003-10-16 Merck & Co., Inc. Method of treating cancer
GB0215823D0 (en) * 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
US20040102360A1 (en) 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
CA2529341A1 (en) 2003-06-24 2005-01-06 Isis Innovation Limited Reagents and methods for the formation of disulfide bonds and the glycosylation of proteins
CN100447139C (zh) 2003-07-08 2008-12-31 诺瓦提斯公司 苯磺酰氨基化合物和含有这些化合物的药物组合物
WO2005090461A2 (en) 2004-03-19 2005-09-29 The Tapemark Company Thermoplastic films and methods for making
EP1730124A4 (en) 2004-03-26 2009-04-01 Amphora Discovery Corp Certain compounds based on triazole, compositions and applications thereof
SE0402635D0 (sv) 2004-10-29 2004-10-29 Astrazeneca Ab Chemical compounds
DE102005011822A1 (de) * 2005-03-15 2006-09-21 Merck Patent Gmbh Phthalazinone
ATE487706T1 (de) 2005-10-06 2010-11-15 Sanofi Aventis Cyclische n-ä1,3,4ü-thiadiazol-2-yl- benzsulfonamide, verfahren zu deren herstellung und deren verwendung als arzneimittel
WO2007106391A1 (en) 2006-03-10 2007-09-20 Lymphosign Inc. Compounds for modulating cell proliferation, compositions and methods related thereto
KR20150038395A (ko) 2006-04-04 2015-04-08 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
US20080153789A1 (en) 2006-12-26 2008-06-26 Femmepharma Holding Company, Inc. Topical administration of danazol
EP2291349A2 (en) 2008-04-14 2011-03-09 The Board of Regents of The University of Texas System Small molecule inhibitors of the pleckstrin homology domain and methods for using same
WO2010085968A1 (en) * 2008-12-30 2010-08-05 European Molecular Biology Laboratory (Embl) Toluidine sulfonamides and their use as hif-inhibitors
CN102448951B (zh) * 2009-04-06 2017-05-10 安吉奥斯医药品有限公司 丙酮酸激酶m2调节剂、治疗组合物和相关使用方法
EP2477625A4 (en) 2009-09-14 2012-10-24 Phusis Therapeutics Inc PHARMACEUTICAL COMPOSITIONS AND FORMULATIONS COMPRISING PLECKSTRINE HOMOLOGY DOMAIN INHIBITORS AND METHODS OF USE
WO2012138938A1 (en) * 2011-04-05 2012-10-11 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of tra kinase
WO2014093988A2 (en) 2012-12-14 2014-06-19 Phusis Therapeutics, Inc. Methods and compositions for inhibiting cnksr1

Also Published As

Publication number Publication date
US20150307482A1 (en) 2015-10-29
MX2015007608A (es) 2016-04-13
MX372739B (es) 2020-05-06
AU2013358876B2 (en) 2018-05-10
EP2931280B1 (en) 2018-02-14
CA2895162A1 (en) 2014-06-19
US9340532B2 (en) 2016-05-17
EP2931280A2 (en) 2015-10-21
AU2013358876A1 (en) 2014-06-19
CA2895162C (en) 2021-03-09
WO2014093988A3 (en) 2014-08-07
JP2016508969A (ja) 2016-03-24
JP6357292B2 (ja) 2018-07-11
EP2931280A4 (en) 2016-06-01
WO2014093988A2 (en) 2014-06-19

Similar Documents

Publication Publication Date Title
IN2015DN00127A (es)
BR112013025006A2 (pt) composições e métodos para inibição de expressão do gene tmprss6
CO7111289A2 (es) Compuestos inhibidores de metaloenzimas
IL252063A0 (en) dna-pk suppressors, preparations containing them and their uses
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
CR20140024A (es) Compuestos inhibidores de metaloenzimas
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
CO7020912A2 (es) Inhibidores de bromodominios
ZA201506452B (en) 3-pyrimidin-4-yl-oxazolidin -2-ones as inhibitors of mutant idh
SG11201406948PA (en) Substituted 3-haloallylamine inhibitors of ssao and uses thereof
MX393754B (es) Metodos y composiciones para inhibir cnksr1
CO7091177A2 (es) Inhibidores de la beta-secretasa
IN2014DN08481A (es)
UY33930A (es) Inhibidores novedosos de quinasas
MX2014007840A (es) Dihidrodiazpinocarbazolonas tetra o penta-cicliclas fusionadas como inhibidores de poli (adp-ribosa) polimerasa (parp).
MX2020001756A (es) Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos.
MY199591A (en) Activator composition and method for making concrete
ZA201602311B (en) (aza)pyridopyrazolopyrimidinones and indazolopyrimidinones as inhibitors of fibrinolysis
PH12014501032A1 (en) 2-thiopyrimidinones
MX337094B (es) Proceso e intermediarios para preparar inhibidores de integrasa.
IN2014DN09450A (es)
EP3074022A4 (en) Compositions and methods for inhibiting intercellular interactions
IN2014DN00254A (es)
PL2888228T3 (pl) Inhibitory oddziaływania CD40-TRAF6
GB201312311D0 (en) Uses of enzyme inhibitors